Basket cover image
15 handpicked stocks

Age-Reversal Biotech

Invest in pioneering companies that are redefining aging as a treatable condition. These carefully selected biotechs are developing groundbreaking therapies to extend healthy lifespans and potentially reverse cellular damage, creating an entirely new frontier in medicine.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 1 day ago | Published at June 17

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

LGVN

Longeveron Inc

LGVN

Current price

$0.74

Its lead product, Lomecel-B, is a regenerative medicine being developed to address aging-related frailty and other conditions of old age.

IPSC

CENTURY THERAPEUTICS INC

IPSC

Current price

$0.57

The company's platform is built on induced pluripotent stem cells (iPSCs), a cornerstone technology for cellular reprogramming and regenerative medici...

The company's platform is built on induced pluripotent stem cells (iPSCs), a cornerstone technology for cellular reprogramming and regenerative medicine.

SANA

SANA BIOTECHNOLOGY INC

SANA

Current price

$3.33

It focuses on engineering cells as medicines, including the use of hypoimmune pluripotent stem cells to regenerate damaged tissues without rejection.

About This Group of Stocks

1

Our Expert Thinking

Aging is being transformed from an inevitable process to a modifiable condition. These companies are at the forefront of developing technologies to extend healthspan—the period of life spent in good health—by targeting the root causes of aging rather than just treating symptoms.

2

What You Need to Know

This is a high-risk, high-reward investment theme. These clinical-stage biotechs are developing cutting-edge technologies like senolytics, cellular reprogramming, and gene editing. Success could mean revolutionary new treatments, but the path to regulatory approval is complex and uncertain.

3

Why These Stocks

Each company was selected for its dedicated focus on core aging pathways and progress in clinical development. Their work spans removing senescent cells, reprogramming cellular behavior, editing genes, and repairing DNA damage—all fundamental approaches to addressing aging at its biological roots.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+656.11%

Group Performance Snapshot

656.11%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 656.11% over the next year.

13 of 14

Stocks Rated Buy by Analysts

13 of 14 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🧬

The Next Medical Frontier

Aging is being redefined as a treatable condition, not an inevitable decline. These companies are creating entirely new markets that could transform healthcare as we know it.

💡

Breakthrough Science Momentum

Recent clinical successes and scientific breakthroughs are accelerating investment in this space. The companies making meaningful progress now could become tomorrow's biotech giants.

🚀

Early Mover Advantage

These smaller biotechs represent a ground-floor opportunity in what could become a trillion-dollar industry addressing humanity's most universal concern: healthy aging.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Uncle Sam's Semiconductor Stake

Uncle Sam's Semiconductor Stake

The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.

View stocks
The Cybersecurity Consolidation Wave

The Cybersecurity Consolidation Wave

Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.

View stocks
American Chipmakers: A Tariff-Driven Shift

American Chipmakers: A Tariff-Driven Shift

President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.